Eli Lilly says it is filing lawsuits against six entities it alleges are selling illegal versions of its experimental weight-loss drug, retatrutide. The company contends the products are being offered outside the proper regulatory channels and marketed as weight-loss treatments.
Lilly also says it is asking U.S. regulators to take stronger action to curb the so-called black market. Multiple outlets describe the targeted sellers as including compounding pharmacies, medical spas and online vendors that promote retatrutide for weight loss. Reports also note that sellers are alleged to use “research-use only” claims to justify the sales.
While the coverage centers on the same legal action and product, the outlets differ in emphasis. CBS and Yahoo highlight Lilly’s broader push to target the illicit market, while The Hill provides additional detail on the types of businesses named and the alleged marketing tactics. Business Line similarly focuses on the company’s regulatory request alongside the lawsuits.
